PMID- 34033159
OWN - NLM
STAT- MEDLINE
DCOM- 20220118
LR  - 20220118
IS  - 1365-2303 (Electronic)
IS  - 0956-5507 (Linking)
VI  - 32
IP  - 5
DP  - 2021 Sep
TI  - Validation of ROS1 by immunohistochemistry against fluorescent in situ 
      hybridisation on cytology and small biopsy samples in a large teaching hospital.
PG  - 621-630
LID - 10.1111/cyt.12994 [doi]
AB  - OBJECTIVE: Rearranged ROS1, present in 1%-2% of non-small cell lung cancer 
      (NSCLC) patients, usually young, never or light smokers, is assessed by 
      fluorescence in situ hybridization (FISH) to determine eligibility for tyrosine 
      kinase inhibitors (TKI). Immunohistochemistry (IHC) for the protein product of 
      ROS1 rearrangement, a cost-effective alternative, is validated on cytology and 
      small biopsy samples. METHODS: From 1 March to 31 December 2019, cytology cell 
      blocks and small biopsy samples from a selected cohort of NSCLC patients were 
      concurrently tested for ROS1 gene rearrangement by Vysis 6q22 Break Apart FISH 
      probe and IHC using Cell Signalling D4D6 antibody. Mismatch cases were tested by 
      an RNA fusion next generation sequencing (NGS) panel. RESULTS: In a prospective 
      population of 95 cases, 91 were negative and two were positive by both FISH and 
      IHC. Both dual positive cases were female never smokers and benefited from TKI 
      treatment. Another two cases were positive by FISH but negative by IHC and repeat 
      by NGS showed one to be negative but one failed. Turnaround time for IHC was 0 to 
      8 days from request to authorisation, whilst that of FISH was 9 to 42 days at a 
      cost of  pound51 and  pound159 respectively. CONCLUSION: IHC to assess for the protein 
      product of ROS1 gene rearrangement on cytology cell blocks and small biopsy 
      samples in a routine setting is a promising screening method to assess 
      eligibility for TKI treatment with positive and indeterminate cases confirmed by 
      FISH or NGS as it has good negative predictive value, faster turnaround time and 
      is cost effective, with proven technical and clinical validation.
CI  - (c) 2021 John Wiley & Sons Ltd.
FAU - Narine, Nadira
AU  - Narine N
AUID- ORCID: 0000-0001-7563-329X
AD  - Manchester Cytology Centre, Manchester University NHS Foundation Trust, 
      Manchester, UK.
FAU - Wallace, Andrew
AU  - Wallace A
AD  - Genomic Diagnostics Laboratory, Manchester University NHS Foundation Trust, 
      Manchester, UK.
FAU - Dore, Jonathan
AU  - Dore J
AD  - Genomic Diagnostics Laboratory, Manchester University NHS Foundation Trust, 
      Manchester, UK.
FAU - O'Leary-Jackson, Simon
AU  - O'Leary-Jackson S
AD  - Manchester Cytology Centre, Manchester University NHS Foundation Trust, 
      Manchester, UK.
FAU - Al Najjar, Haider
AU  - Al Najjar H
AD  - Department of Respiratory Medicine, Manchester University NHS Foundation Trust, 
      Manchester, UK.
FAU - Bailey, Simon
AU  - Bailey S
AD  - Department of Respiratory Medicine, Manchester University NHS Foundation Trust, 
      Manchester, UK.
FAU - Khan, Kashif
AU  - Khan K
AD  - Department of Respiratory Medicine, Manchester University NHS Foundation Trust, 
      Manchester, UK.
FAU - Teng, Benjamin
AU  - Teng B
AD  - Department of Respiratory Medicine, Manchester University NHS Foundation Trust, 
      Manchester, UK.
FAU - Qasim, Muhammad
AU  - Qasim M
AD  - Department of Respiratory Medicine, Manchester University NHS Foundation Trust, 
      Manchester, UK.
FAU - Shelton, David
AU  - Shelton D
AD  - Manchester Cytology Centre, Manchester University NHS Foundation Trust, 
      Manchester, UK.
FAU - Holbrook, Miles
AU  - Holbrook M
AD  - Manchester Cytology Centre, Manchester University NHS Foundation Trust, 
      Manchester, UK.
FAU - Abbasi, Salma
AU  - Abbasi S
AD  - Department of Respiratory Medicine, Manchester University NHS Foundation Trust, 
      Manchester, UK.
FAU - Carter, Matthew
AU  - Carter M
AD  - Department of Oncology, The Christie NHS Foundation Trust, Manchester, UK.
FAU - Irion, Luciane
AU  - Irion L
AD  - Department of Histopathology, Manchester University NHS Foundation Trust, 
      Manchester, UK.
FAU - Al-Habba, Samer
AU  - Al-Habba S
AD  - Department of Histopathology, Manchester University NHS Foundation Trust, 
      Manchester, UK.
FAU - Lindsay, Colin
AU  - Lindsay C
AD  - Department of Oncology, The Christie NHS Foundation Trust, Manchester, UK.
FAU - Blackhall, Fiona
AU  - Blackhall F
AD  - Department of Oncology, The Christie NHS Foundation Trust, Manchester, UK.
FAU - Rana, Durgesh
AU  - Rana D
AD  - Manchester Cytology Centre, Manchester University NHS Foundation Trust, 
      Manchester, UK.
LA  - eng
GR  -  pound3000.00/Pfizer UK/
PT  - Journal Article
DEP - 20210615
PL  - England
TA  - Cytopathology
JT  - Cytopathology : official journal of the British Society for Clinical Cytology
JID - 9010345
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (ROS1 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy/*methods
MH  - Carcinoma, Non-Small-Cell Lung/diagnosis/metabolism
MH  - Cytodiagnosis/*methods
MH  - Female
MH  - Hospitals, Teaching/methods
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Lung Neoplasms/diagnosis/metabolism
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Protein-Tyrosine Kinases/*metabolism
MH  - Proto-Oncogene Proteins/*metabolism
OTO - NOTNLM
OT  - FISH
OT  - IHC
OT  - ROS1
OT  - biopsy
OT  - cell block
OT  - cytology
EDAT- 2021/05/26 06:00
MHDA- 2022/01/19 06:00
CRDT- 2021/05/25 14:11
PHST- 2021/03/25 00:00 [revised]
PHST- 2020/08/28 00:00 [received]
PHST- 2021/04/26 00:00 [accepted]
PHST- 2021/05/26 06:00 [pubmed]
PHST- 2022/01/19 06:00 [medline]
PHST- 2021/05/25 14:11 [entrez]
AID - 10.1111/cyt.12994 [doi]
PST - ppublish
SO  - Cytopathology. 2021 Sep;32(5):621-630. doi: 10.1111/cyt.12994. Epub 2021 Jun 15.